MICHAEL BOHR: Open Payments
NPI 1275082992 · MOOSIC, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,970 in 134 payments from 15 companies in 2025. Trend: 2023 $1,159 · 2024 $1,672 · 2025 $1,970
Food & beverage: $1,970
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 47 | $431 |
| Otsuka America Pharmaceutical, Inc. | 19 | $422 |
| ABBVIE INC. | 18 | $219 |
| E.R. Squibb & Sons, L.L.C. | 11 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $151 |
| Alkermes, Inc. | 6 | $114 |
| Lundbeck LLC | 6 | $109 |
| Neurocrine BioSciences, Inc. | 3 | $73 |
| Supernus Pharmaceuticals, Inc. | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
Products named: CAPLYTA, REXULTI, VRAYLAR, COBENFY, TRINTELLIX, ABILIFY MAINTENA, LYBALVI, INGREZZA.
Industry payments across PA — which companies pay providers there.
